EPHA4 and breast cancer: To determine the pathological relevance of secretory hRNase 1 and EphA4 activation, we evaluated the expression levels of secretory hRNase 1 in plasma samples and phospho-EphA4 levels in matched tumor tissues from patients with breast cancer; notably, a significantly positive correlation was observed (p = 0.042; Fig. 7a).